The Potential of Biotechnology Investments in Selected Eastern European Countries: Lost Chances

1. Adelman, D. & Holman, C., (2009). “Misplaced Fears in the Legislative Battle Over Affordable Biotech Drugs”. Idea, Vol.50 No.4, pp.565–591.Search in Google Scholar

2. AWA, (2012). “Lifescience Zurich Booklet”, Zurich.Search in Google Scholar

3. Bloomberg, (2014). “Bloomberg”. visual data.Search in Google Scholar

4. Boschma, R., Heimeriks, G. & Balland, P.-A., (2014). “Scientific knowledge dynamics and relatedness in biotech cities”. Research Policy, Vol.43 No.1, pp.107–114.10.1016/j.respol.2013.07.009Search in Google Scholar

5. Brada, J.C., Kutan, A.M. & Yigit, T.M., (2006). “The effects of transition and political instability on foreign direct investment inflows.”. The Economics of Transition, Vol.14 No.4, pp.649–680.10.1111/j.1468-0351.2006.00272.xSearch in Google Scholar

6. Coan, T.D. & Ron, E., (2001). “Generic Biologics: The Next Frontier”, London.Search in Google Scholar

7. Consortium, S.G. et al., (2008). “Protein production and purification”., Vol.5 No.2.Search in Google Scholar

8. Debackere, K. & Veugelers, R., (2005). “The role of academic technology transfer organizations in improving industry science links”. Research Policy, Vol.34 No.3, pp.321–342.10.1016/j.respol.2004.12.003Search in Google Scholar

9. EAER, (2014). “Swiss Biotech Report 2014”,Search in Google Scholar

10. Van Epps, H.L., (2006). “Singapore’s multibillion dollar gamble.”. The Journal of experimental medicine, Vol.203 No.5, pp.1139–42.10.1084/jem.20060895Search in Google Scholar

11. Ereky, K., (1919). “Biotechnologie der Fleisch-, Fett-, und Milcherzeugung im landwirtschaftlichen Grossbetriebe: für naturwissenschaftlich gebildete Landwirte verfasst”, Berlin: P. Parey.Search in Google Scholar

12. Ernst & Young, (2013). “Beyond borders: global biotechnology report 2013”. Beyond borders, No.27.Search in Google Scholar

13. Essendorfer, S., Diaz-Rainey, I. & Falta, M., (2015). “Creative destruction in Wall Street’s technological arms race: Evidence from patent dataNo Title”. Technological Forecasting and Social Change.10.1016/j.techfore.2014.11.012Search in Google Scholar

14. Fári, M.G. & Kralovánszky, U.P., (2006). “The founding father of biotechnology: Károly (Karl) Ereky”. International Journal of Horticultural Science, Vol.12 No.1, pp.9–12.10.31421/IJHS/12/1/615Search in Google Scholar

15. Farrell, D., (2005). “Offshoring: Value creation through economic change”. Journal of Management Studies, Vol.42 No.3, pp.675–683.10.1111/j.1467-6486.2005.00513.xSearch in Google Scholar

16. Gerstein, M.B. et al., (2007). “What is a gene, post-ENCODE? History and updated definition.”. Genome research, Vol.17 No.6, pp.669–81.10.1101/gr.6339607Search in Google Scholar

17. Glick, J.L., (2008). “Biotechnology business models work: Evidence from the pharmaceutical marketplace”. Journal of Commercial Biotechnology, Vol.14 No.2, pp.106–117.10.1057/palgrave.jcb.3050085Search in Google Scholar

18. Gregersen, N. et al., (2006). “Protein misfolding and human disease.”. Annual review of genomics and human genetics, Vol.7, pp.103–24.10.1146/annurev.genom.7.080505.115737Search in Google Scholar

19. Grullon, G., Lyandres, E. & Zhdanov, A., (2012). “Real Options, Volatility, and Stock Returns”. Journal of Finance, Vol.67 No.4, pp.1499–1537.10.1111/j.1540-6261.2012.01754.xSearch in Google Scholar

20. Hollanders, H. & Es-Sadki, N., (2014). “Innovation Union Scoreboard 2014”, Maastricht.Search in Google Scholar

21. Hulse, J.H., (2004). “Biotechnologies: past history, present state and future prospects”. Trends in Food Science & Technology, Vol.15 No.1, pp.3–18.10.1016/S0924-2244(03)00157-2Search in Google Scholar

22. IMD, (2013). “International Institute for Management Development”. world competitiveness online.Search in Google Scholar

23. JLL, (2012). “NoLife Sciences Outlook Switzerland. 2012”, Zurich.Search in Google Scholar

24. Junkunc, M.T., (2007). “Managing radical innovation: The importance of specialized knowledge in the biotech revolution”. Journal of Business Venturing, Vol.22 No.3, pp.388–411.10.1016/j.jbusvent.2006.04.004Search in Google Scholar

25. Kim, W.C. & Mauborgne, R., (2004). “Blue ocean strategy”. Harvard Business Review, Vol.82 No.10, pp.76–84.Search in Google Scholar

26. Kishore, G.M. & Shewmaker, C., (1999). “Biotechnology: Enhancing human nutrition in developing and developed worlds”. Proceedings of the National Academy of Sciences, Vol.96 No.11, pp.5968–5972.10.1073/pnas.96.11.5968Search in Google Scholar

27. Kochanova, A., (2012). “The Impact of Bribery on Firm Performance: Evidence from Central and Eastern European Countries”, The Center for Economic Research and Graduate Education - Economic Institute, Prague.10.2139/ssrn.2191094Search in Google Scholar

28. Kogan, L., Papanikolaou, D. & Stoffman, N., (2015). “Winners and Losers: Creative Destruction and the Stock Market”,Search in Google Scholar

29. Kolev, A. & Saget, C., (2005). “Understanding youth labour market disadvantage: Evidence from south-east Europe”. International Labour Review, Vol.144 No.2, pp.161–187.10.1111/j.1564-913X.2005.tb00564.xSearch in Google Scholar

30. Kozlowski, J., Radosevic, S. & Ircha, D., (1999). “History matters: The inherited disciplinary structure of the post-communist science in countries of central and eastern Europe and its restructuring”. Scientometrics, Vol.45 No.1, pp.137–166.10.1007/BF02458473Search in Google Scholar

31. Lim, L.P.L. & Gregory, M.J., (2004). “Singapore’s biomedical science sector development strategy: Is it sustainable?”. Journal of Commercial Biotechnology, Vol.10 No.4, pp.352–362.10.1057/palgrave.jcb.3040093Search in Google Scholar

32. Meyer, M., (2003). “Academic entrepreneurs or entrepreneurial academics? research-based ventures and public support mechanisms”.10.1111/1467-9310.00286Search in Google Scholar

33. MLSC, (2014). “Massachusetts Life Sciences Center”.Search in Google Scholar

34. Mungiu-pippidi, A., (2014). “The Transformative Power of Europe Revisited”. Journal of Democracy, Vol.25 No.1, pp.20–32.10.1353/jod.2014.0003Search in Google Scholar

35. NCES, (2014). “National Center for Education Statistics”.Search in Google Scholar

36. Nicholson, S., Danzon, P. & McCullough, J., (2002). “Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality”, Cambridge, MA.10.3386/w9007Search in Google Scholar

37. OECD, (2014). “Defining biotechnology”.Search in Google Scholar

38. OECD, (2013). “Employment and Labour Markets: Key Tables from OECD”, OECD Productivity Statistics.Search in Google Scholar

39. Owen-Smith, J. & Powell, W.W., (2006). “Accounting for Emergence and Novelty in Boston and Bay Area Biotechnology”. In P. Braunerhjelm & M. P. Feldman, eds. Cluster Genesis: Technology-Based Industrial Development. Oxford Scholarship, pp. 1–39.10.1093/acprof:oso/9780199207183.003.0004Search in Google Scholar

40. Pearson, H., (2006). “Genetics: what is a gene?”. Nature, Vol.441 No.7092, pp.398–401.Search in Google Scholar

41. Rader, R.A., (2008). “(Re)defining biopharmaceutical.”. Nature biotechnology, Vol.26 No.7, pp.743–51.10.1038/nbt0708-743Search in Google Scholar

42. Radosevic, S. & Auriol, L., (1999). “Patterns of restructuring in research, development and innovation activities in central and eastern European countries: an analysis based on S&T indicators”. Research Policy, Vol.28 No.4, pp.351–376.10.1016/S0048-7333(98)00124-3Search in Google Scholar

43. Rossi, M., Tarba, S.Y. & Raviv, A., (2013). “Mergers and acquisitions in the hightech industry: a literature review”. International Journal of Organizational Analysis, Vol.21 No.1, pp.66–82.10.1108/19348831311322542Search in Google Scholar

44. Schafer, S., (2011). “Top 20 Countries in ALL FIELDS”. Essential Science Indicators.Search in Google Scholar

45. Schwab, K. & Sala-i-Martín, X., (2014). “The Global Competitiveness Report”,Search in Google Scholar

46. Senker, J., Enzing, C. & Reiss, T., (2012). “Biotechnology in Central and Eastern Europe: An overview of performance and policy system”. In Exploring Central and Eastern Europe’s Biotechnology Landscape. pp. 13–35.10.1007/978-90-481-9784-2_2Search in Google Scholar

47. ShanghaiRanking, (2014). “Academic Ranking of World Universities 2013”.Search in Google Scholar

48. UNSD, (2011). “Expert Group discusses future work on classifications”, New York.Search in Google Scholar

49. Waldmann, T. a, (2003). “Immunotherapy: past, present and future.”. Nature medicine, Vol.9 No.3, pp.269–77.10.1038/nm0303-269Search in Google Scholar

50. Walsh, G., (2014). “Biopharmaceutical benchmarks 2014”. Nature biotechnology, Vol.32 No.7, pp.992–1000.10.1038/nbt.3040Search in Google Scholar

51. WEF, (2014). “Labor market efficiency”. In The Global Competitiveness Report 2013-2014. World Economic Forum, p. 10.Search in Google Scholar

52. Wolfe, R.M., (2012). “Business R & D Performed in the United States Cost $ 291 Billion in 2008 and $ 282 Billion in 2009”,Search in Google Scholar

53. Wong, P.-K., Ho, Y.-P. & Singh, A., (2009). “Industrial Cluster Development and Innovation in Singapore”. In A. Kuchiki & M. Tsuji, eds. From Agglomeration to Innovation. IDE-JETRO, pp. 50–116.Search in Google Scholar

54. WorldBank, (2014)(a). “GDP growth (annual %)”. World Development Indicators.Search in Google Scholar

55. WorldBank, (2014)(b). “Research and development expenditure (% of GDP)”. World Development Indicators.Search in Google Scholar

56. WorldBank, (2014)(c). “Scientific and technical journal articles”. World Development Indicators.Search in Google Scholar

57. Wurm, F.M., (2004). “Production of recombinant protein therapeutics in cultivated mammalian cells.”. Nature biotechnology, Vol.22 No.11, pp.1393–8.10.1038/nbt1026Search in Google Scholar

58. Yamaner, M., (2012). “Federal Funds for Research and Development: Fiscal Year 2009-11”,Search in Google Scholar

59. Zürcher, J., (2005). “Swiss Biotech Report 2005”, Winterthur.Search in Google Scholar